Novartis takes home rights to Lubris’ eye drug
Novartis has elected to exercise an option to in-license experimental eye drug ECF843 from US biopharma Lubris.
Read More
Tag: ECF843
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
